title: Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes.
authors.affiliation: Unit of Hematology and Stem Cell Transplantation, IRCCS Casa Sollievo della Sofferenza Hospital, 71013 S. Giovanni Rotondo, Italy. p.musto@tin.it
authors.forename: Pellegrino
authors.initials: P
authors.lastname: Musto
authors.forename: Antonietta
authors.initials: A
authors.lastname: Falcone
authors.forename: Grazia
authors.initials: G
authors.lastname: Sanpaolo
authors.forename: Michele
authors.initials: M
authors.lastname: Bisceglia
authors.forename: Rosella
authors.initials: R
authors.lastname: Matera
authors.forename: Angelo Michele
authors.initials: AM
authors.lastname: Carella
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000754:Anemia, Refractory, with Excess of Blasts / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D001803:Blood Transfusion; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D004921:Erythropoietin / Q000097:blood; D005260:Female; D005319:Fetal Hemoglobin / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D004921:Erythropoietin; D013792:Thalidomide; D005319:Fetal Hemoglobin